Fennec Pharmaceuticals Inc. Common Stock
FENCStock
$10.44+21.70%52W
Market Cap$369.95M
P/E—
Div yield—
Beta1.05
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)30.01%
Price vs S&P 500 (4W)17.71%
VGM Score64.12
Market Capitalization$369.95M
Earnings Surprise History
Q1 260.01est. -0.01
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.23
4.17
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FENCFennec Pharmaceuticals Inc. Common Stock | D | A | B | $10.44 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Fennec Pharmaceuticals is a biopharmaceutical company commercializing PEDMARK, a novel formulation designed to prevent cisplatin-induced hearing loss in children undergoing chemotherapy. The company addresses a significant side effect of cancer treatment with a first-in-class therapeutic approach. Operations are based in the United States.